Objective. To determine how practicing clinicians evaluate patients with sensorineural hearing loss (SNHL) and to analyze the cost-effectiveness of current algorithms in the evaluation of these patients.
H earing loss (HL) is the most common sensory deficit in humans: 2 or 3 of every 1000 children born in the United States have congenital HL, .50% of which is genetic, significant enough to affect speech and language development. 1, 2 While early diagnosis in infants facilitates appropriate intervention and habilitation and thus speech and language development, 1 identifying a specific etiology at any age affects clinical care and HL management by providing prognostic information to patients and their families, refining genetic counseling, clarifying habilitation options, and identifying associated comorbidities.
The diagnostic complexity of nonsyndromic HL is reflected by the myriad of tests that are available and have been advocated as part of the standard evaluation for this condition. The list includes laboratory studies, such as an electrocardiogram (EKG), urinalysis, and thyroid hormone level; imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI) of the temporal bone and renal ultrasound; and referrals to specialists, such as ophthalmologists and genetic counselors. While not all tests are invariably ordered, these tests are costly and timeconsuming and can have a low diagnostic rate and, therefore, a low value in establishing an etiology for the HL. 3 Genetic testing for HL first became available in the late 1990s when variants in GJB2 were recognized as a major cause of severe to profound congenital autosomal recessive and sporadic nonsyndromic HL in developed countries. 4 Because GJB2 has a single coding exon, genetic testing was simple; however, with the discovery of additional genetic causes of autosomal recessive and autosomal dominant nonsyndromic hearing loss, in the early 21st century, testing transitioned from a GJB2-only strategy to serial gene-by-gene Sanger-based screening using patient-specific phenotypic data to drive the selection strategy for genetic testing. 5 For example, in an infant with congenital severe to profound deafnessin the absence of causal variants in GJB2, which was often screened as a ''first step'' because sequencing was easy-the presence of delayed developmental motor milestones, such as delayed sitting and delayed walking, would prompt genetic screening of the Usher syndrome type 1 genes. This step was a formidable undertaking because of the number of genes involved in Usher syndrome type 1 and their large size (6 genes totaling 189 exons and 69,800 base pairs). 6 Recent advances in sequencing technologies now provide clinicians with a powerful diagnostic tool to evaluate HL and inform patient management. 6 All genes implicated in nonsyndromic HL can be screened simultaneously with outstanding accuracy to establish a genetic diagnosis. This test can be ordered first, and the genetic report can then inform additional tests likely to be of benefit in patient care. 6 For example, in an infant with sporadic moderate HL with causative mutations in SLC26A4 identified by genetic testing, a CT scan to assess the enlarged vestibular aqueduct should be ordered; in contrast, if the HL was secondary to 2 variants in TECTA, no further testing would be warranted.
Several recent studies have examined the diagnostic yield of the battery of tests available for evaluation of patients with HL, and they have found wide ranges of clinical utility for these tests and recommended tiered evaluation involving genetic testing. [7] [8] [9] A recent position statement by the American College of Medical Genetics advocated a tiered approach to the evaluation of HL to save costs, reduce incidental findings, and improve overall diagnostic yield. 1 As there have been no studies to examine current practice in the evaluation of HL in the wake of comprehensive genetic testing and the American College of Medical Genetics recommendations, we created an interactive survey to assess clinical preferences for tests and referral patterns in the evaluation of HL. The survey presents 4 simulated cases, each of which offers to the clinician 2 encounters during which the patient's HL can be evaluated. The responses provide a representative sample to determine the current algorithm that clinicians use when evaluating patients with sensorineural hearing loss (SNHL). We then compare the cost-effectiveness of the different algorithms used when evaluating patients with SNHL. We hypothesize that there remains high variability in the evaluation of these patients and that comprehensive genetic testing is not yet uniformly utilized among health care providers.
Materials and Methods

Survey Population
Health care professionals who care for patients with HL were targeted for survey distribution through 2 large professional societies: the American Society of Pediatric Otolaryngologists and the American Society of Human Geneticists. The American Society of Pediatric Otolaryngologists is a society of .500 members, mostly pediatric otolaryngologists. The American Society of Human Geneticists is a society of nearly 8000 members, whose membership includes researchers, academicians, clinicians, and other individuals with an interest in human genetics. The survey distributed to the American Society of Human Geneticists called specifically for clinicians of geneticists involved directly in the care of patients with HL. Although our survey targeted geneticists and pediatric otolaryngologists, the breadth of the American Society of Human Geneticists population is broad; thus, we allowed practitioners to identify themselves as ''pediatrician'' or ''other.'' Private practitioners who were ''associated with a medical center'' were classified as private practice.
Survey Design and Testing
The survey instrument was designed using information reported in the literature and investigator-based hypotheses. 1 We utilized simulated case-based scenarios as a means to analyze practice patterns. The survey begins with a brief section that solicits respondent-specific data, including practice demographics and training experience. Four patient cases then follow, each of which includes a brief history and audiometric data. Respondents are asked to order those diagnostic tests that they would typically request in the evaluation of a patient with HL. The test battery includes repeat audiometry, audiometry on parents of family members, congenital infection screening, thin-cut CT of the temporal bone, MRI of the temporal bone, EKG, urinalysis, ophthalmology consultation, genetics referral, genetic testing of GJB2, and multigene (comprehensive) genetic testing. After the first ''encounter,'' results of the requested tests are provided, and a second encounter is simulated, at which time additional testing can be ordered. At the conclusion of the second encounter, a summary of the case, including the final diagnosis and plan, is provided. There are no ''right'' or ''wrong'' answers. The full survey is available in the appendix (available online at www.otojournal.org of supplemental).
Cases Presented
The cases were selected to include a representative cross section of patients with SNHL: The Qualtrics online survey program (Qualtrics, Inc, Provo, Utah) was used to administer the survey. The instrument underwent trial testing by screening committees from the American Society of Pediatric Otolaryngologists and the American Society of Human Geneticists for functionality, quality, and adherence to specific societal guidelines. This study was granted exemption from consent by the Institutional Review Board of the University of Iowa.
Cost Data
As there is high variability in health care costs throughout the nation, we used costs at our home institution to represent the costs of the tests available through the case-based scenarios. Comprehensive genetic testing is available as a send-out test, regardless of institution, for $1500. As insurance reimbursement is dependent on patient, comorbidities, state, insurance company, and so on, we did not include this variable in our cost analysis.
Data Collection
The initial request for survey participation was sent by e-mail using each society's respective LISTSERV. An introductory message from the research team and a survey link were included in the e-mail. A follow-up reminder was sent to the same list 4 weeks later. The survey was closed after response rates decreased.
Measures, Variables, and Data Analysis
Questions with free-response answers that were categorical variables were organized and tabulated, with the most common answers being reported. Data were collated in Microsoft Excel and analyzed in SPSS 21. We divided respondents into 4 categories for statistical analysis: occupation, time when clinical training was completed, type of practice (academic vs private practice), and number of patients evaluated per month ( 
Results
Study Demographics
Demographic results are shown in Table 1 . In sum, 111 respondents started the survey, and 87 completed it (78% completion rate). Of the 24 respondents who did not complete the survey, 80% (19 of 24) were identified as otolaryngologists, 13% (3 of 24) as geneticists, and 8% (2 of 24) did not respond with an occupation. The respondents identified themselves most commonly as otolaryngologists (61%), followed by geneticists (29%), as well as other clinicians (10%), including pediatricians (3%), genetic counselors, (3%), and 1 each of pediatric neurologist, ophthalmologist, and other (no answer). The majority of respondents (58 of 87, 67%) completed their clinical training between the 1950s and the 1990s; the remainder (29 of 87, 23%) competed their clinical training in the 2000s and 2010s. These 2 groups were used for statistical analysis, as genetic testing for HL became widely available in the late 1990s. The majority of respondents were part of an academic practice (70%, 61 of 87), while the remainder were part of a private practice or a private practice affiliated with a medical center (grouped as ''private practice''; 29%, 25 of 87).
The majority of respondents (75 of 87, 86%) were fellowship trained, with pediatric otolaryngology (63%) being the most common fellowship, followed by clinical or medical genetics (23%). The majority of respondents (61 of 87, 70%) were also in academic practice. Although the majority of otolaryngologists (47 of 57, 83%) were pediatric otolaryngologists, for analysis purposes, we grouped all otolaryngologists and referred to them as ''otolaryngologists.'' For no-answer responses, the value was excluded from demographic analysis. b Other occupations include pediatrician (n = 3), genetic counselor (n = 3), pediatric neurologist (n = 1), ophthalmologist (n = 1), other-no response (n = 1).
Of the respondents, 57% (50 of 87) saw 1 to 5 patients per month with HL, while 41% (36 of 87) saw .5. We found that of the respondents who saw .5 patients per month, 95% (35 of 37) were otolaryngologists; the remaining 2 respondents identified as a pediatrician and a genetic counselor. Table 2 shows the overall frequency of respondents ordering each type of test across all 4 cases, including both encounters for each case (8 total encounters). Ophthalmology consultation, CT of temporal bone, and genetics consult were ordered at least once by 85%, 83%, and 82% of respondents, respectively, making them the most frequently ordered test or consult. Repeat audiometric testing, EKG, and congenital infection screen were ordered least frequently (ordered at least once by 62%, 63%, and 63% of respondents, respectively). Multigene (comprehensive) genetic testing was ordered slightly more than single-gene (GJB2) testing (78% vs 74%, respectively). For the majority of diagnostic tests, there was no significant difference in ordering frequency based on occupation. However, compared with geneticists, otolaryngologists were significantly more likely to order repeat audiograms or auditory brainstem response (77% vs 32%, P \ .01) and significantly less likely to order comprehensive genetic testing (70% vs 96%, P \ .01).
Diagnostic Tests Ordered
Differences in tests ordered reflected time of clinical training. Respondents who completed training after 1990 were significantly more likely to order MRI and EKG as compared with their more senior colleagues (90% vs 55% for MRI, P \ .01; 79% vs 55% for EKG, P \ .02).
Respondents who see more patients were also significantly more likely to repeat auditory brainstem response of audiogram testing and less likely to order comprehensive genetic testing (83% vs 46% for auditory brainstem response of audiogram, P \ .01; 67% vs 86% for comprehensive genetic testing, P \ .03). There were no significant differences in the overall frequency of tests ordered across cases based on practice type (academic vs private practice; Table 2 ).
Tests Ordered by Encounter
As shown in Figure 1 , the most commonly ordered test on the first encounter, when averaged across all 4 cases, was CT of the temporal bone (40%), followed by ophthalmology (39%) and genetics consultations (37%). The least commonly ordered tests on the first encounter were comprehensive genetic testing (20%), congenital infection screen (21%), and EKG (24%). On the second encounter, the most commonly ordered test was comprehensive genetic testing (30%), followed by genetics consultation (13%) and congenital infection screen (8%).
Tests Ordered by Case
We also examined the tests ordered by respondents for each case when both encounters were combined to better understand overall ordering patterns ( Figure 2) . Congenital infection screens were ordered less frequently in adult patients (cases 1 and 3 at 3% and 7%, respectively). Case 3 involved the only patient with unilateral hearing loss. Respondents ordered CT of the temporal bone most frequently in this case (ordered by 60% of respondents, compared with 47%, 45%, and 38% for cases 1, 2, and 4, respectively). Respondents ordered genetic testing least frequently for this case, including single-gene testing (ordered by 18% vs 26%, 46%, and 38% for cases 1, 2, and 4, respectively) as well as multigene testing (ordered by 36% vs 68%, 59%, and 40%, for cases 1, 2, and 4, respectively).
Costs of Tests Ordered
On average, 4 tests were ordered per encounter with no significant differences between groups. The most expensive tests were MRI ($5163), CT of temporal bone ($2047), and comprehensive genetic testing ($1500). The least expensive tests were urinalysis ($47), congenital infection screen ($100), and EKG ($258; Table 3 ).
Respondents spent an average of $4756 per case ( Table  4 ). Case 1 was the least expensive ($4544), while case 4 was the most expensive ($5325). On average across all 4 cases, otolaryngologists spent significantly more money evaluating HL than did geneticists ($5152 vs $3807, P \ .02). Respondents who completed clinical training after 1990 also spent significantly more per case than their older counterparts ($5252 vs $4508, P \ .01). Academicians spent more than private practitioners ($4816 vs $4444), as did persons who saw more patients ($5085 vs $4437), although these differences were not significant.
Discussion
The goal of this study was to determine how practicing clinicians evaluate patients with SNHL. Until recently, the primary objective was to exclude syndromic forms of hearing loss that carry associated morbidities, such as kidney disease, blindness, or cardiac arrhythmias, with a myriad of tests and referrals. However, since the introduction of clinical genetic testing for SNHL, the focus has shifted to establishing an etiologic diagnosis using genetic testing. The American College of Medical Genetics recently released a guideline 1 that included comprehensive genetic testing as part of the standard evaluation; however, no otolaryngologists were included as part of the drafting committee. In this study, we used a survey simulating 4 case encounters to determine how clinicians-otolaryngologists and nonotolaryngologistsevaluate SNHL on a daily basis.
Our analysis reveals that despite differences in training, geneticists and otolaryngologists are statistically equally likely to order audiograms of parents, congenital infection screen, CT and MRI of the temporal bone, EKG, urinalysis, ophthalmology consultation, genetics consultation, and DFNB1 genetic testing. The areas of difference are in ordering repeat audiograms, which are ordered more frequently by otolaryngologists, and multipanel genetic testing, which is ordered more frequently by geneticists. Despite being more likely to order comprehensive genetic testing initially, geneticists ultimately spend significantly less than otolaryngologists in their workup of these patients.
Establishing a diagnosis for SNHL is challenging, and the relative value of the tests to consider can be confusing. The results of our survey attest to this complexity and suggest that there is no universally accepted diagnostic algorithm. Rather than following consistent evidence-based algorithms, we suspect that preferences reflect clinical familiarity with individual tests. As newer tests, such as comprehensive genetic testing, have become available, integrating them into the evaluation process can be slow, especially if clinicians are unfamiliar with the technology and have difficulty in interpreting the final report. Because clinical geneticists may be more familiar with interpreting the results of comprehensive genetic testing as compared with otolaryngologists, they may be more comfortable ordering this test. The current consensus is that HL should be evaluated using a tiered testing approach that emphasizes history and physical examination, followed by genetic testing, with imaging studies considered if genetic testing is negative or inconclusive. 1 This consensus is based on the premise that the diagnosis be made using the fewest tests possible and that the various tests have differing diagnostic utility. 3, [7] [8] [9] [10] [11] [12] While sensitivity and positive diagnostic rates vary widely, imaging studies are thought to have the highest diagnostic yield (about 30% for CT and 26% for MRI in systematic reviews 10, 11 ) and are certainly better than genetic testing if it is limited only to GJB2 mutation screening. 7, 12 Recent studies, however, show that comprehensive genetic testing has a diagnostic rate of 37% to 60%, [13] [14] [15] making it the best test to order in the evaluation of SNHL.
There are several well-documented reasons to support the use of comprehensive genetic testing in the diagnosis of SNHL. As the cornerstone of precision medicine for hearing health care, the results of comprehensive genetic testing for HL can lead to improved diagnosis and clinical management of patients with HL. Examples include the diagnosis of Jervell and Lange-Nielsen syndrome, Usher syndrome, deafnessinfertility syndrome, and mitochondrial DNA-related hearing loss. 6 However, not only is comprehensive genetic testing clinically appropriate, but it is also cost-effective. As a single test, it is less expensive than any temporal bone-imaging modality, and as multiple studies have shown, it has the highest single-test positive diagnostic rate overall. 3, 6, 10, 11, [13] [14] [15] The notable exception is unilateral hearing loss, as these patients infrequently have identifiable causes of genetic hearing loss even with comprehensive genetic testing. 6 In the costconscious climate of today's health care industry, otolaryngologists may benefit from utilizing comprehensive genetic testing earlier in their diagnostic algorithm, similar to the geneticists in this study, who demonstrated a more costeffective evaluation of patients with SNHL in our analysis.
The strength of this study is its use of simulated case scenarios to determine how providers evaluate patients with SNHL. However, there are several limitations that warrant mention. First, the American Society of Pediatric Otolaryngologists was the only resource used to disseminate this survey to otolaryngologists, and as such, these results are likely only generalizable to the pediatric otolaryngology population. Second, the cost-effectiveness analysis is limited because we did not consider insurance reimbursement. By presenting our data in the context of hospital charges for individual tests and consultations, however, we sought to eliminate inconsistencies introduced by including insurance reimbursement, which can be highly variable. Thus, our cost data do not represent the ultimate out-of-pocket cost to the patient but rather the cost charged by the hospital and so may not be generalizable in all circumstances.
In conclusion, while recent guidelines support the use of comprehensive genetic testing early in the evaluation of SNHL as a step to increase the diagnostic rate and decrease the utilization of uninformative tests, we found significant variability in respondents' testing approach. Although an algorithm utilizing comprehensive genetic testing has the potential to decrease health care expenditures in the evaluation of HL, clinicians have not uniformly incorporated this new test into their clinical practice.
